| 1 | | | |
|----|---|--|--|
| 2 | High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA | | |
| 3 | booster vaccination | | |
| 4 | | | |
| 5 | Lidya Handayani Tjan, MD, PhD; Koichi Furukawa, MD; Yukiya Kurahashi, MD; | | |
| 6 | Silvia Sutandhio, MD; Mitsuhiro Nishimura, PhD; Jun Arii, DVM, PhD; Yasuko Mori, MD | | |
| 7 | PhD | | |
| 8 | | | |
| 9 | Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate | | |
| 10 | School of Medicine, Kobe, Hyogo 650-0017, Japan | | |
| 11 | | | |
| 12 | Corresponding author: | | |
| 13 | Prof. Yasuko Mori | | |
| 14 | Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate | | |
| 15 | School of Medicine. | | |
| 16 | 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Japan, 650-0017 | | |
| 17 | Tel: +81-78-382-6272; Fax: +81-78-382-6879 | | |
| 18 | E-mail: <u>ymori@med.kobe-u.ac.jp</u> | | |

| 20 | Abstract |
|----|----------|
| 20 | Abstract |

| 21 | The VOC of SARS-CoV-2, Omicron (BA.1, BA.1.1, BA.2, or BA.3), is associated with an | | | |
|----|---|--|--|--|
| 22 | increased risk of reinfection. BA.2 has become the next dominant variant worldwide. | | | |
| 23 | Although BA.2 infection has been shown to be mild illness, its high transmissibility will | | | |
| 24 | result in high numbers of cases. In response to the surge of Omicron BA.1 cases, booster | | | |
| 25 | vaccination was initiated in many countries. But there is limited evidence regarding the | | | |
| 26 | effectiveness of a booster vaccination against BA.2. We collected blood samples from 84 | | | |
| 27 | physicians at Kobe University Hospital, Japan, in January 2022 ~7 months after they had | | | |
| 28 | received two BNT162b2 vaccinations and ~2 weeks after their booster vaccination. We | | | |
| 29 | performed a serum neutralizing assay against BA.2 using authentic virus. | | | |
| 30 | Although most of the participants had no or a very low titer of neutralizing antibody against | | | |
| 31 | BA.2 at 7 months after two BNT162b2 vaccinations, the titer increased significantly at 2 | | | |
| 32 | weeks after the booster vaccination. | | | |
| 33 | | | | |
| 34 | | | | |

36 Introduction

| 37 | The most recently designated VOC of SARS-CoV-2, Omicron, is associated with an | | | | |
|----|--|--|--|--|--|
| 38 | increased risk of reinfection ¹ . Among four sub-lineages of Omicron (BA.1, BA.1.1, BA.2, | | | | |
| 39 | and BA.3), BA.1 has spread to >151 countries and is responsible for the greatly increased | | | | |
| 40 | number of COVID-19 cases worldwide. However, Omicron BA.2 has also been detected in | | | | |
| 41 | \geq 85 countries and became the dominant lineage in 18 countries by mid-February 2022 ² . BA.2 | | | | |
| 42 | has become the next dominant variant worldwide. | | | | |
| 43 | A recent epidemiological study in South Africa suggested that the clinical profile of illness | | | | |
| 44 | caused by BA.1 infection is similar to that caused by BA.2 ³ . Although BA.2 infection has | | | | |
| 45 | been shown to be mild illness, its high transmissibility will result in high numbers of cases | | | | |
| 46 | with considerable societal impacts, e.g., greater work absences, including healthcare and | | | | |
| 47 | public employees. | | | | |
| 48 | In response to the surge of Omicron BA.1 cases, booster vaccination was initiated in many | | | | |
| 49 | countries. We and others have previously reported that BA.1 escapes two doses of | | | | |
| 50 | BNT162b2 mRNA vaccine-induced neutralization and that a booster (3rd) vaccination is | | | | |
| 51 | required to induce the neutralizing antibody against BA.1 ^{4,5} . But there is limited evidence | | | | |
| 52 | regarding the effectiveness of a booster vaccination against BA.2 ⁶ . | | | | |
| 53 | | | | | |
| 54 | Methods | | | | |
| 55 | We collected blood samples from 84 physicians at Kobe University Hospital, Japan, in | | | | |
| 56 | January 2022 (median age 44 years, IQR 33-58) ~7 months after they had received two | | | | |
| 57 | BNT162b2 vaccinations and ~2 weeks after their booster vaccination. We performed a serum | | | | |
| 58 | neutralizing assay against BA.2 using authentic virus as described ⁴ . No participants had a | | | | |
| 59 | history of SARS-CoV-2 infection. The study was approved by the ethical committee of the | | | | |

| 60 Kobe University Graduate School of Medicine (approval code: B200200). All part | cipants |
|---|---------|
|---|---------|

- 61 were recruited with their written consent.
- 62

63 **Results**

- 64 The results demonstrated that similar to $BA.1^4$, most of the participants had no or a very low
- titer of neutralizing antibody against BA.2 at 7 months after two BNT162b2 vaccinations
- (GMT 1.18, 95%CI: 1.09-1.27). However, the titer increased significantly at 2 weeks after
- 67 the booster vaccination (GMT 36.44, 95%CI: 30.53–43.50), p<0.001 (Fig. 1).
- 68

69 **Discussion**

- 70 These results indicate that the booster vaccination could induce neutralizing immunity against
- 71 Omicron BA.2 (as it has against BA.1), and that a booster dose of BNT162b2 mRNA vaccine
- 72 induces a high cross-neutralizing response against SARS-CoV-2 variants⁴, indicating the
- 73 booster vaccination is meaningful and hopeful for the suppression of BA.2 pandemic and can
- 74 activate memory B cells that could produce neutralizing antibodies recognizing epitopes
- 75 conserved among SARS-CoV-2 variants.

76

77 Conflict of interest

- All authors declare no conflicts of interest with respect to this letter. Authors have submitted
- 79 the ICMJE Form for Disclosure of Conflicts of Interest.

80

81 Acknowledgments

- 82 We gratefully acknowledge Kazuro Sugimura MD, PhD (Superintendent, Hyogo Prefectural
- 83 Hospital Agency and Professor, Kobe University) for giving his full support to this study. We

- 84 also thank the National Institute of Infectious Disease Japan for providing the SARS-CoV-2
- 85 Omicron variants BA.2.

87 Figure Legend

Figure. 1. Neutralizing antibody titers against Omicron BA.2 in BNT162b2 mRNA-

vaccinated adult males (n=84) at 7 months after they had received two vaccine doses and at 2

90 weeks after a booster vaccination. The limit of detection is displayed with a dotted horizontal

- 91 line and the horizontal line shows the geometric mean titer. The titers were compared by the
- 92 two-sample Wilcoxon rank-sum (Mann-Whitney) test; two-tailed p-values were calculated.
- 93

94 **References**

95 Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron 1. 96 Variant from Previous SARS-CoV-2 Infection. Ν Engl Med. Feb 9 J 97 2022;doi:10.1056/NEJMc2200133

98 World Health Organization (WHO). COVID-19 Weekly Epidemiological Update Edition 2. 99 80. 2022. Accessed 2022. Updated 22 February Mar 15, 100 https://apps.who.int/iris/bitstream/handle/10665/352199/CoV-weekly-sitrep22Feb22-101 eng.pdf

1023.Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the103SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. Jan 291042022;399(10323):437-446. doi:10.1016/S0140-6736(22)00017-4

105 Furukawa K, Tjan LH, Kurahashi Y, et al. Acquired neutralizing breadth against SARS-4. 106 CoV-2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the 107 vaccine efficacy. medRxiv [preprint]. 108 2022;doi:10.1101/2022.01.25.22269735doi:https://doi.org/10.1101/2022.01.25.22269735 109 Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of SARS-5. 110 CoV-2 Omicron Infection. Ν Enal Med. Feb 3 2022;386(5):492-494. J 111 doi:10.1056/NEJMc2119358

1126.Chen LL, Chu AW, Zhang RR, Hung IF, To KK. Serum neutralisation of the SARS-CoV-2113omicron sublineage BA.2.The Lancet Microbe.Mar 28 2022;doi:10.1016/S2666-1145247(22)00060-X

| | 512 | P <.001 |
|---|-------------------|----------------|
| ÷ | 512- | |
| ains | 256- | • |
| . age | 128- | - |
| titer 2 | 64- | |
| ody 1 BA | 64- 32- 16- | |
| Neutralizing antibody titer against Omicron BA.2 | 16- | - |
| ing a Om | 8- | • • |
| caliz | 4- | - |
| leuti | 2- <2- | |
| | <2 - | |
| | | 2° . 0 |
| | c c | dos poost |
| | , the | odoses pooster |
| 3 | iter | N 31. |
| 71110 | | odoses pooster |